This downregulation of EMT markers corresponded with impaired migratory and invasive capabilities in NOD2-depleted cells, suggesting that NOD2 promotes the mesenchymal phenotype that facilitates GBM cell invasion and therapeutic resistance. The gene discussed is NOD2; the disease is glioblastoma.